Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented CDA technology and proprietary cancer-detection device.
Jan 04, 2022
AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in Q1, 2022
Dec 10, 2021
Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical Journal
Nov 26, 2021
AnPac Bio Reports Nine Months Ended September 30, 2021, Same Period Achieved Record Revenue Increased By 55.3% While Non-GAAP Net Loss Reduced by 6.8%